drugset / Trial / NCT02006121

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

NCT02006121

Phase 3 Completed 107 enrolled Britannia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical treatment. The secondary objective of the study was to investigate the safety and tolerability of apomorphine continuous subcutaneous therapy.

Timeline

Start
2014-03-03
Primary completion
2016-06-06
Completion
2017-06-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apomorphine Unknown 3 mg Subcutaneous
Comparator Apomorphine Unknown 8 mg Subcutaneous

Indications